References
- Lands W. E., Samuelsson B. Phospholipid precursors of prostaglandins. Biochim. Biophys. Acta 1968; 164(2)426–429, [PUBMED], [INFOTRIEVE]
- Hamberg M., Svensson J., Wakabayashi T., Samuelsson B. Isolation and structure of two prostaglandin endoperoxides that cause platelet aggregation. Proc. Natl. Acad. Sci. U. S. A. 1974; 71(2)345–349, [PUBMED], [INFOTRIEVE]
- Needleman P., Turk J., Jakschik B. A., Morrison A. R., Lefkowith J. B. Arachidonic acid metabolism. Ann. Rev. Biochem. 1986; 55: 69–102, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Smith W. L., DeWitt DL. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. Adv. Immun. 1996; 62: 167–215, [PUBMED], [INFOTRIEVE], [CSA]
- Kraemer S. A., Meade S. A., DeWitt DL. Prostaglandin endoperoxide synthase gene structure: identification of the transcriptional start site and 5′-flanking regulatory sequences. Arch. Biochem. Biophys. 1992; 293: 391–400, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Fletcher B. S., Kubuju D. A., Perrin D. M., Herschman H. R. Structure of the mitogen-inducible TIS10 gene and demonstration that the TIS10-encoded protein is a functional prostaglandin G/H synthase. J. Biol. Chem. 1992; 267: 4338–4344, [PUBMED], [INFOTRIEVE]
- Smith W. L., DeWitt D. L. Biochemistry of prostaglandin endoperoxide H synthase-1 and synthase-2 and their differential susceptibility to nonsteroidal anti-inflammatory drugs. Semin. Nephrol. 1995; 15: 179–194, [PUBMED], [INFOTRIEVE], [CSA]
- Crofford L. J. COX-1 and COX-2 tissue expression: implications and predictions. J. Rheumatol. 1997; 24(Suppl 49)15–19
- Appleby S. B., Ristimaki A., Neilson K., Narko K., Hla T. Structure of the human cyclooxygenase-2 gene. Biochem. J. 1994; 302: 723–727, [PUBMED], [INFOTRIEVE]
- Seibert K., Zhang Y., Leahy K. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc. Natl. Acad. Sci. U. S. A. 1994; 91: 12013–12017, [PUBMED], [INFOTRIEVE], [CSA]
- deBrum-Fernandes A. J., Laporte S., Heroux M., Lora M., Patry C., Menard H. A., Dumais R., Leduc R. Expression of prostaglandin endoperoxide synthase-1 and prostaglandin endoperoxide synthase-2 in human osteoblasts. Biochem. Biophys. Res. Commun. 1994; 198: 944–960
- Jackson B. A., Goldstein R. H., Roy R., Cozzani M., Taylor L., Polgar P. Effects of transforming growth factor beta and interleukin-1 beta on expression of cyclooxygenase 1 and 2 and phospholipase A2 mRNA in lung fibroblasts and endothelial cells in culture. Biochem. Biophys. Res. Commun. 1993; 197: 1465–1474, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Angel J., Berenbaum F., Le Denmat C., Nevalainen T., Masliah J., Fournier C. Interleukin-1-induced prostaglandin E2 biosynthesis in human synovial cells involves the activation of cytosolic phospholipase A2 and cyclooxygenase-2. Eur. J. Biochem. 1994; 226: 125–131, [PUBMED], [INFOTRIEVE]
- Mertz P. M., DeWitt D. L., Stetler-Stevenson E. G., Wahl L. M. Interleukin 10- suppression of monocyte prostaglandin H synthase-2. Mechanism of inhibition of prostaglandin-dependent matrix metalloproteinase production. J. Biol. Chem. 1994; 269: 21322–21329, [PUBMED], [INFOTRIEVE]
- Ristimaki A., Garfinkel S., Wessendorf J., Maciag T., Hla T. Induction of cyclooxygenase-2 by interleukin-1 alpha. Evidence for post-transcriptional regulation. J. Biol. Chem. 1994; 269: 11769–11775, [PUBMED], [INFOTRIEVE]
- Pilbeam C. C., Kawaguchi H., Hakeda Y., Voznesensky O., Alander C. B., Raisz L. G. Differential regulation of inducible and constiutiove prostaglandin endoperoxide synthase in osteoblastic MC3T3-E1 cells. J. Biol. Chem. 1993; 268: 25643–25649, [PUBMED], [INFOTRIEVE]
- Crofford L. J., Wilder R. L., Ristimaki A. P., Sano H., Remmers E. F., Epps H. R., Hla T. Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. Effects of interleukin-1 beta, phorbol ester, and corticosteroids. J. Clin. Invest. 1994; 93: 1095–1101, [PUBMED], [INFOTRIEVE], [CSA]
- Matsuura H., Sakaue M., Subbaramaiah K., Kamitani H., Eling T. E., Dannenberg A. J., Tanabe T., Inoue H., Arata J., Jetten A. M. Regulation of cyclooxygenase-2 by interferon γ and transforming growth factor α in normal human epidermal keratinocytes and squamous carcinoma cells. J. Biol. Chem. 1999; 274(41)29138–29148, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Araki E., Forster C., Dubinsky J. M., Ross M. E., Iadecola C. Cyclooxygenase-2 inhibitor ns-398 protects neuronal cultures from lipopolysaccharide-induced neurotoxicity. Stroke 2001; 32(10)2370–2375, [PUBMED], [INFOTRIEVE]
- Boulven I., Palmier B., Robin P., Vacher M., Harbon S., Leiber D. Platelet-derived growth factor stimulates phospholipase C-gamma 1, extracellular signal-regulated kinase, and arachidonic acid release in rat myometrial cells: contribution to cyclic 3′, 5′-adenosine monophosphate production and effect on cell proliferation. Biol. Reprod. 2001; 65(2)496–506, [PUBMED], [INFOTRIEVE], [CSA]
- Sheng H., Shao J., Dubois R. N. K-Ras-mediated increase in cyclooxygenase 2 mRNA stability involves activation of the protein kinase B1. Cancer Res. 2001; 61(6)2670–2675, [PUBMED], [INFOTRIEVE]
- Takeuchi T., Tsuboi T., Arai M., Togari A. Adrenergic stimulation of osteoclastogenesis mediated by expression of osteoclast differentiation factor in MC3T3-E1 osteoblast-like cells. Biochem. Pharmacol. 2001; 61(5)579–586, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Pyeon D., Diaz F. J., Splitter G. A. Prostaglandin E(2) increases bovine leukemia virus tax and pol mRNA levels via cyclooxygenase 2: regulation by interleukin-2, interleukin-10, and bovine leukemia virus. J. Virol. 2000; 74(12)5740–5745, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Konturek P. C., Hartwich A., Zuchowicz M., Labza H., Pierzchalski P., Karczewska E., Bielanski W., Hahn E. G., Konturek S. J. Helicobacter pylori, gastrin and cyclooxygenases in gastric cancer. J. Phys. Pharmacol. 2000; 51(4 pt 1)737–749, [CSA]
- Anderson G. D., Hauser S. D., Bremer M. E., McGarity K. L., Isakson P. C., Gregory S. A. Selective inhibition of cyclooxygenase-2 reverses inflammation and expression of COX-2 and IL-6 in rat adjuvant arthritis. J. Clin. Invest. 1996; 97: 2672–2679, [PUBMED], [INFOTRIEVE], [CSA]
- Eberhart C. E., Coffey R. J., Radhika A., Giardello F. M., Ferrenbach S., DuBois R. N. Upregulation of cyclooxygenase-2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterol 1994; 107: 1183–1188, [CSA]
- Sung J. J.Y., Leung W. K., Go M. Y.Y., To K. F., Cheng A. S.L., Ng E. K.W., Chan F. K.L. Cyclooxygenase-2 expression in Helicobacter pylori-associated premalignant and malignant gastric lesions. Am. J. Pathol. 2000; 157(3)729–735, [PUBMED], [INFOTRIEVE]
- Kazuhiko U., Ichikura T., Mochizuki H. Expression of cyclooxygenase-2 in human gastric adenomas and adenocarcinomas. J. Surg. Oncol. 2001; 76: 26–30, [CROSSREF]
- Morris C. D., Armstrong G. R., Bigley G., Green H., Attwood S. E.A. Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. Am. J. Gastroenterol. 2001; 96(4)990–996, [PUBMED], [INFOTRIEVE]
- Ratnasinghe D., Tangrea J., Roth M. J., Dawsey S., Hu N., Anver M., Wang Q. H., Taylor P. R. Expression of cyclooxygenase-2 in human squamous cell carcinoma of the esophagus; An immunohistochemical survey. Anticancer Res. 1999; 19: 171–174, [PUBMED], [INFOTRIEVE], [CSA]
- Shiota G., Okubo M., Noumi T., Noguchi N., Oyama K., Takano Y., Yashima K., Kishimoto Y., Kawasaki H. Cyclooxygenase-2 expression in hepatocellular carcinoma. Hepato-Gastroenterol. 1999; 46: 407–412, [CSA]
- Grossman E. M., Longo W. E., Panesar N., Mazuski J. E., Kaminski D. L. The role of cyclooxygenase enzymes in the growth of human gall bladder cancer cells. Carcinogenesis 2000; 21(7)1403–1409, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Hayashi N., Yamamoto H., Hiraoka N., Dono K., Ito Y., Okami J., Kondo M., Nagano H., Umeshita K., Sakon M., Matsuura N., Nakamori S., Monden M. Differential expression of cyclooxygenase-2 (COX-2) in human bile duct epithelial cells and bile duct neoplasm. Hepatol 2001; 34: 638–650, [CROSSREF]
- Tucker O. N., Dannenberg A. J., Yang E. K., Zhang F., Teng L., Daly J. M., Soslow R. A., Masferrer J. L., Woerner B. M., Koki A. T., Fahey T. J. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res. 1999; 59: 987–990, [PUBMED], [INFOTRIEVE]
- Achiwa H., Yatabe Y., Hida T., Kuroishi T., Kozaki K. I., Nakamura S., Ogawa M., Sugiura T., Mitsudomi T., Takahasi T. Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin. Cancer Res. 1999; 5: 1001–1005, [PUBMED], [INFOTRIEVE], [CSA]
- Hida T., Yatabe Y., Achiwa H., Muramatsu H., Kozaki K. I., Nakamura S., Ogawa M., Mitsudomi T., Sugiura T., Takahashi T. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res. 1998; 58: 3761–3764, [PUBMED], [INFOTRIEVE]
- Wolff H., Saukkonen K., Anttila S., Karjalainen A., Vainio H., Ristimaki A. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res. 1998; 58: 4997–5001, [PUBMED], [INFOTRIEVE]
- Kulkarni S., Rader J. S., Zhang F., Liapis H., Koki A. T., Masferrer J. L., Subbaramaiah K., Dannenberg A. J. Cyclooxygenase-2 is overexpressed in human cervical cancer. Clin. Cancer Res. 2001; 7: 429–434, [PUBMED], [INFOTRIEVE], [CSA]
- Sales K. J., Katz A. A., Davis M., Hinz S., Soeters R. P., Hofmeyr M. D., Millar R. P., Jabbour H. N. Cyclooxygenase-2 expression and prostaglandin E2 synthesis are up-regulated in carcinomas of the cervix: a possible autocrine/paracrine regulation of neoplastic cell function via EP2/EP4 receptors. J. Clin. Endocrinol. Metab. 2001; 86(5)2243–2249, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Shirahama T., Arijma J. I., Akiba S., Sakakura C. Relation between cyclooxygenase-2 expression and tumor invasiveness and patient survival in transitional cell carcinoma of the urinary bladder. Cancer 2001; 92: 188–193, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Marrogi A., Pass H. I., Khan M., Metheny-Barlow L. J., Harris C. C., Gerwin B. I. Human mesothelioma samples overexpress both cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (NOS2): in vitro antiproliferative effects of a COX-2 inhibitor. Cancer Res. 2000; 60: 3696–3700, [PUBMED], [INFOTRIEVE]
- Liu X. H., Rose D. P. Differential expression and regulation of cyclooxygenase-1 and -2 in two human breast cancer cell lines. Cancer Res. 1996; 56: 5125–5127, [PUBMED], [INFOTRIEVE]
- Mestre J. R., Chan G., Zhang F., Yank E. K., Sacks P. G., Boyle J. O., Shah J. P., Edelstein D., Subbaramaiah K., Dannenberg A. J. Inhibition of cyclooxygenase-2 expression. An approach to preventing head and neck cancer. Ann. N.Y. Acad. Sci. 1999; 889: 62–71, [PUBMED], [INFOTRIEVE]
- Kagoura M., Toyoda M., Matsui C., Morohashi M. Immunohistochemical expression of cyclooxygenase-2 in skin cancers. J. Cutan. Pathol. 2001; 28(6)298–302, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Howe L. R., Subbaramaiah K., Brown A. M., Dannenberg A. J. Cyclooxygenase-2: a target for the prevention and treatment of breast cancer. Endocr.-Relat. Cancer 2001; 8(2)97–114, [CSA], [CROSSREF]
- Denkert C., Kobel M., Berger S., Siegert A., Leclere A., Trefzer U., Hauptmann S. Expression of cyclooxygenase 2 in human malignant melanoma. Cancer Res. 2001; 61(1)303–308, [PUBMED], [INFOTRIEVE]
- Kirschenbaum A., Liu X., Yao S., Levine A. C. The role of cyclooxygenase-2 in prostate cancer. Urology 2001; 58(2 Suppl 1)127–131, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Khuri K. R., Wu H., Lee J. J., Kemp B. L., Lotan R., Lippman S. M., Feng L., Hong W. K., Xu X. C. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin. Cancer Res. 2001; 7(4)861–867, [PUBMED], [INFOTRIEVE], [CSA]
- Ohno R., Yoshingaga K., Fujita T., Hasegawa K., Iseki H., Tsunozaki H., Ichikawa W., Nihei Z., Sugihara K. Depth of invasioon parallels increased cyclooxygenase-2 levels in patients with gastric carcinoma. Cancer 2001; 91(10)1876–1881, [PUBMED], [INFOTRIEVE]
- Fujita T., Matsui M., Takaku K., Uetake H., Ichikawa W., Taketo M. M. Size-and invasion-dependent increase in cyclooxygenase 2 levels in human colorectal carcinomas. Cancer Res. 1998; 58: 4823–4826, [PUBMED], [INFOTRIEVE]
- Sheehan K. M., Sheahan K., O'Donoghue D. P., MacSweeney F., Conroy R. M., Fitzgerald D. J., Murray F. E. The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA 1999; 282: 1254–1257, [PUBMED], [INFOTRIEVE]
- Chen W. S., Wei S. J., Liu J. M., Hsiao M., Kou-Lin J., Yang W. K. Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2 selective inhibitor, etodolac. Int. J. Cancer 2001; 91: 894–899, [PUBMED], [INFOTRIEVE]
- Tomozawa S., Tsuno N. H., Sunami E. Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancer. Br. J. Cancer 2000; 83: 324–328, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Lim H. Y., Joo H. J., Choi J. H., Yi J. W., Yang M. S., Cho D. Y., Kim H. S., Nam D. K., Lee K. B., Kim H. C. Increased expression of cyclooxygenase-2 protein in human gastric carcinoma. Clin. Cancer Res. 2000; 6(2)519–525, [PUBMED], [INFOTRIEVE], [CSA]
- DuBois R. N., Giardello F. M., Smalley W. E. Nonsteroidal anti-inflammatory drugs, eicosanoids, and colorectal cancer prevention. Gastroenterol. Clin. North Am. 1996; 25: 773–781, [PUBMED], [INFOTRIEVE], [CSA]
- Anonymous. Findings from the aspirin component of the ongoing Physicians' Health Study. N. Engl. J. Med. 1988; 318(4)262–264
- Paganini-Hill A., Chao A., Ross R. K., Henderson B. E. Aspirin use and chronic diseases: a cohort study of the elderly. BMJ 1989; 299(6710)1247–1250
- Collet J. P., Sharpe C., Belzile E., Boivin J. F., Hanley J., Abenhaim L. Colorectal cancer prevention by non-steroidal anti-inflammatory drugs: effects of dosage and timing. Br. J. Cancer 1999; 81(1)62–68, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Farrow D. C., Vaughan T. L., Hansten P. D., Stanford J. L., Risch H. A., Gammon M. D., Chow W. H., Dubrow R., Ahsan H., Mayne S. T., Schoenbertg J. B., West A. B., Rotterdam H., Fraumeni J. J., Jr., Blot W. J. Use of aspirin and other non-steroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol. Biol. Prev. 1998; 7(2)97–102
- Cerhan J. R., Anderson K. E., Janney C. A., Vachon C. M., Habermann T. M., Witzig T. E. Association of aspirin and other non-steroidal anti-inflammatory drug use with incidence of non-Hodgkin lymphoma in a cohort of older women. Blood 2001; 98: 336a
- Pollard M., Luckert P. H. Effect of indomethacin on intestinal tumors induced in rats by the acetate derivative of methylnitrosamine. Science 1981; 214: 558–559, [PUBMED], [INFOTRIEVE]
- Moorgehn M., Ince P., Finney K. J., Sunter J. P., Appleton J. R., Watson A. J. A. protective effect of sulinadac againset chemically-induced primary colonic tumours in mice. J. Pathol. 1988; 156: 341–347
- Lynch N. R., Castes M., Astoin M., Salomon J. C. Mechanism of inhibition of tumour growth by aspirin and indomethacin. Br. J. Cancer 1978; 38: 503–512, [PUBMED], [INFOTRIEVE]
- Young M. R., Knies S. Prostaglandin E production by Lewis lung carcinoma: mechanism for tumor establishment in vivo. J. Natl. Cancer Inst. 1984; 72: 919–922, [PUBMED], [INFOTRIEVE]
- Hial V., Horakova Z., Shaff F. E., Beaven M. A. Alteration of tumor growth by aspirin and indomethacin: studies with two transplantable tumors in mouse. Eur. J. Pharmacol. 1976; 37: 367–376, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Murasaki G., Zenser T. V., Davis B. B., Cohen S. M. Inhibition by aspirin of N-(4-(5-nitro-2-furyl)-2-thiazolyl) formamide-induced bladder carcinogenesis and enhancement of forestomach carcinogenesis. Carcinogenesis 1984; 5: 53–55, [PUBMED], [INFOTRIEVE]
- Carter C. A., Ip M. M., Ip C. A comparison of effects of the prostaglandin synthesis inhibitors indomethacin and carprofen on 7, 12-dimethylbenz[a]anthracene-induced mammary tumorigenesis in rats fed different amounts of essential fatty acid. Carcinogenesis 1989; 10: 1369–1374, [PUBMED], [INFOTRIEVE]
- Takahashi M., Furukawa F., Toyoda K., Sato H., Hasegawa R., Imaida K. Effects of various prostaglandin synthesis inhibitors on pancreatic carcinogenesis in hamsters after initiation with N-nitrosobis(2-oxopropyl)amine. Carcinogenesis 1990; 11: 393–395, [PUBMED], [INFOTRIEVE]
- Oshima M., Dinchuk J. E., Kargman S. L., Oshima H., Hancock B., Kwong E., Trzaskos J. M., Evans J. F., Taketo M. M. Suppression of intestinal polyposis in Apc716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996; 87: 803–809, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Sheng H., Shao J., Kirkland S. C., Isakson P., Coffey R. J., Morrow J., Beauchamp R. D., DuBois R. N. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J. Clin. Invest. 1997; 99(9)2254–2259, [PUBMED], [INFOTRIEVE], [CSA]
- Masferrer J. L., Leahy K. M., Koki A. T., Zweifel B. S., Settle S. L., Woerner B. M., Edwards D. A., Flickinger A. G., Moore R. J., Seibert K. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 2000; 60(5)1306–1311, [PUBMED], [INFOTRIEVE]
- Waddell W. R., Ganser G. F., Cerise E. J., Lowry R. W. Sulindac for polyposis of the colon. Am. J. Surg. 1989; 157: 175–179, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Nugent K. P., Farmer K. C., Spigelman A. D., Williams C. B., Phillips R. K. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br. J. Surg. 1993; 80(12)1618–1619, [PUBMED], [INFOTRIEVE], [CSA]
- Giardiello F. M., Hamilton S. R., Krush A. J., Piantadosi S., Hylind L. M., Celano P., Booker S. V., Robinson C. R., Offerhaus G. J. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N. Engl. J. Med. 1993; 328(18)1313–1316, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Rigau J., Pique J. M., Rubio E., Planas R., Tarrech J. M., Bordas J. M. Effects of long-term sulindac therapy on colonic polyposis. Ann. Intern. Med. 1991; 115: 952–954, [PUBMED], [INFOTRIEVE]
- Lundholm K., Gelin J., Hyltander A., Lonnroth C., Sandstrom R., Svaninger G., Korner U., Gulich M., Karrefors I., Norli B. Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors. Cancer Res. 1994; 54: 5602–5606, [PUBMED], [INFOTRIEVE]
- Form D. M., Auerback R. PGE2 and angiogenesis. Proc. Soc. Exp. Biol. Med. 1983; 172: 214–218, [PUBMED], [INFOTRIEVE]
- Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353–364, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Tsujii M., Kawano S., Tsuji S., Sawaoka H., Hori M., DuBois R. N. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998; 93(5)705–716, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Mesri M., Morales-Ruiz M., Ackermann E. J., Bennett C. F., Pober J. S., Sessa W. C., Altieri D. C. Suppression of vascular endothelial growth factor-mediated endothelial cell protection by survivin targeting. Am. J. Pathol. 2001; 158(5)1757–1765, [PUBMED], [INFOTRIEVE]
- Oshima M., Murai N., Kargman S., Arguello M., Luk P., Kwong E., Taketo M. M., Evans J. F. Chemoprevention of intestinal polyposis in the Apcdelta 715 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res. 2001; 61(4)1733–1740, [PUBMED], [INFOTRIEVE]
- Sheng H., Shao J., Washington M. K., DuBois R. N. Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J. Biol. Chem. 2001; 276(21)18075–18081, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Tsujii M., DuBois R. N. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995; 83(3)493–501, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Sommers C. L., Thompson E. W., Torri J. A., Kemler R., Gelmann E. P., Byers S. W. Cell adhesion molecule uvomorulin expression in human breast cancer cell lines: relationship to morphology and invasive capacities. Cell Growth Differ. 1991; 2(8)365–372, [PUBMED], [INFOTRIEVE]
- Tsujii M., Kawano S., DuBois R. N. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc. Natl. Acad. Sci. U. S. A. 1997; 94(7)3336–3340, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Zhang Z., DuBois R. N. Detection of differentially expressed genes in human colon carcinoma cells treated with a selective COX-2 inhibitor. Oncogene 2001; 20(33)4450–4456, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Hida T., Kozaki K., Muramatsu H., Masuda A., Shimizu S., Mitsudomi T., Sugiura T., Ogawa M., Takahashi T. Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin. Cancer Res. 2000; 6(5)2006–2011, [PUBMED], [INFOTRIEVE], [CSA]
- Yang W. L., Frucht H. Activation of the PPAR pathway induces apoptosis and COX-2 inhibition in HT-29 human colon cancer cells. Carcinogenesis 2001; 22(9)1379–1393, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Kamijo T., Sato T., Nagatomi Y. Induction of apoptosis by cyclooxygenase-2 inhibitors in prostate cancer cell lines. Int. J. Urol. 2001; 8(7)S35–S39, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Zimmerman K. C., Sarbia M., Weber A. A., Borchard F., Gabbert H. E., Schror K. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res. 1999; 59(1)198–204
- Halak B. K., Maguire H. C., Jr., Lattime E. C. Tumor-induced interleukin-10 inhibits type 1 immune responses directed at a tumor antigen as well as a non-tumor antigen present at the tumor site. Cancer Res. 1999; 59: 911, [PUBMED], [INFOTRIEVE]
- Handel-Fernandez M. E., Ching X., Herbert L. M., Lopez D. M. Down-regulation of IL-12, not a shift from a T helper-1 to at T helper-2 phenotype is responsible for impaired IFN-γ production in mammary tumor-bearing mice. J. Immunol. 1997; 158: 280
- Stolina M., Sharma S., Lin Y., Dohadwala M., Gardner B., Luo J., Zhu L., Kronenberg M., Miller P. W., Portanova J., Lee J. C., Dubinett S. M. Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J. Immunol. 2000; 164: 361–370, [PUBMED], [INFOTRIEVE]
- Masferrer J. L., Isakson P. C., Seibert K. Cyclooxygenase-2 inhibitors: a new class of anti-inflammatory agents that spare the gastrointestinal tract. Gastroenterol. Clin. North Am. 1996; 25(2)363–372, [PUBMED], [INFOTRIEVE], [CSA]
- Masferrer J. L., Zweifel B. S., Manning P. T., Hauser S. D., Leahy K. M., Smith W. G., Isakson P. C., Seibert K. Selective inhibition of inducible cyclooxygenase 2 in vivo is anti-inflammatory and nonulcerogenic. Proc. Natl. Acad. Sci. U. S. A. 1994; 91(8)3228–3232, [PUBMED], [INFOTRIEVE], [CSA]
- Silverstein F. E., Faich G., Goldstein J. L., Simon L. S., Pincus T., Whelton A., Makuch R., Eisen G., Agrawal N. M., Stenson W. F., Burr A. M., Zhao W. W., Kent J. D., Lefkowith J. B., Verburg K. M., Geis G. S. Gastrointestinal toxicity with celecoxib vs. non-steroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. JAMA 2000; 284(10)1297–1299, [CROSSREF]
- Mukherjee D., Nissen S. E., Topol E. J. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001; 286(8)954–959, [CROSSREF]
- Lorenz M., Slaughter H. S., Wescott D. M., Carter S. I., Schnyder B., Dinchuk J. E., Car B. D. Cyclooxygenase-2 is essential for normal recovery from 5-fluorouracil-induced myelotoxicity in mice. Exp. Hematol. 2000; 28(7)741–742, [CSA], [CROSSREF]
- Steinbach G., Lynch P. M., Phillips R. K., Wallace M. H., Hawk E., Gordon G. B., Wakabayashi N., Saunders B., Shen Y., Fujimura T., Su L. K., Levin B. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med. 2000; 342(26)1946–1952, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Milas L. Cyclooxygenase-2 (COX-2) enzyme inhibitors as potential enhancers of tumor radioresponse. Semin. Radiat. Oncol. 2001; 11(1)290–299, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Furuta Y., Hunter N., Barkley T., Jr., Hall E., Milas L. Increase in radioresponse of murine tumors by treatment with indomethacin. Cancer Res. 1988; 48(11)3008–3013, [PUBMED], [INFOTRIEVE]
- Steinauer K. K., Gibbs I., Ning S., French J. N., Armstrong J., Knox S. J. Radiation induces upregulation of cyclooxygenase-2 (COX-2) protein in PC-3 cells. Int. J. Radiat. Oncol. Biol. Phys. 2000; 48(2)325–328, [PUBMED], [INFOTRIEVE], [CSA]
- Dicker A. P., Williams T. L., Grant D. S. Targeting angiogenic processes by combination rofecoxib and ionizing radiation. Am. J. Clin. Oncol. 2001; 24(5)438–442, [PUBMED], [INFOTRIEVE], [CSA]
- Kishi K., Petersen S., Petersen C., Hunter N., Mason K., Masferrer J. L., Fofilon P. J., Milas L. Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor. Cancer Res. 2000; 60(5)1326–1331, [PUBMED], [INFOTRIEVE]
- Hsueh C. T., Chiu C. F., Kelsen D. P., Schwartz G. K. Selective inhibition of cyclooxygenase-2 enhances mitomycin-C-induced apoptosis. Cancer Chemother. Pharmacol. 2000; 45(5)389–396, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Sinicrope F. A., Pazdur R., Levin B. Phase I trial of sulindac plus 5-fluorouracil and levamisole: potential adjuvant therapy for colon carcinoma. Clin. Cancer Res. 1996; 2: 37–41, [PUBMED], [INFOTRIEVE], [CSA]